Contents
The Poolbeg Pharma share price is €0.0017 as of May 13th, 2020. This is a decrease of €0.0002 from the previous close of €0.0019 on May 12th, 2020.
The Poolbeg Pharma share price has been on the rise in recent weeks, as investors have become increasingly bullish on the company’s prospects. The stock is up nearly 30% since the start of the year, and analysts believe there is still room for further upside. Poolbeg Pharma is a Dublin-based pharmaceutical company that specializes in developing generic drugs.
The company has been growing rapidly in recent years, as more and more patients switch to cheaper generic drugs. Poolbeg Pharma now has a market share of around 4% in Ireland, and its products are available in over 60 countries worldwide. Investors are betting that Poolbeg Pharma will continue to gain market share globally, as more and more countries adopt generic drugs.
The company is also expanding its product range into new therapeutic areas, which should further boost growth. With strong fundamentals and a bright future ahead, the Poolbeg Pharma share price looks set to continue its upward trend.
Open Orphan is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing orphan drugs for rare diseases and drug repurposing for viral infections. Its lead product candidates include OPNT001, a treatment for the Human metapneumovirus; and OPNT002, which is in development to treat COVID-19.
As of December 31, 2019, Open Orphan had not generated any revenue.
On March 11th, 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic. Subsequently, various governments around the world implemented travel restrictions and lockdowns to contain the spread of the virus.
These steps have adversely impacted global economic activity with widespread implications for businesses across all sectors.
Credit: www.thisismoney.co.uk
This is a difficult question to answer as it depends on a number of factors, including the current market conditions and the company’s financial situation. However, if you are looking for an estimate, we would say that the Poolbeg Pharma share price could drop within the next 6-12 months.
Poolbeg Pharma has its sights on exchange listing
Conclusion
The Poolbeg Pharma share price is up over 4% in early trading today after the company announced that it has signed a major new contract with a leading global pharmaceutical company. Under the terms of the contract, Poolbeg will provide active pharmaceutical ingredients (APIs) to the customer for use in their products. This is a significant win for Poolbeg, and underscores the quality of its API manufacturing capabilities.
The shares have been under pressure in recent months on concerns about slowing sales growth and profitability. However, this new contract provides a boost to both top-line and bottom-line growth, and should help to allay some of those concerns. At the current share price, Poolbeg Pharma is valued at around €1 billion.